Serum Level of Relaxin-2 Correlated to the Diabetic Patients with Coronary Artery Disease

Authors

  • Huda S.Abdulghani Department of Chemistry and Biochemistry, College of Medicine, Mustansiriyah University, Iraq. Author
  • Sura A. Abdulsattar Department of Chemistry and Biochemistry, College of Medicine, Mustansiriyah University, Iraq. Author
  • Essam N.Salman National Diabetes Center for Research and Treatment, Mustansiriyah University,Iraq. Author

DOI:

https://doi.org/10.61841/xcaacj98

Keywords:

Relaxin, Insulin, HbA1c, Coronary Artery Disease, Type 2 Diabetes Mellitus

Abstract

Relaxin has Vasodilatory effects of cardiovascular complication of diabetes through promotes flow and vasodilation in coronary arteries. This study aim to evaluate of relaxin as a biomarker for cardiovascular complication of diabetes. The study included88 Iraqi subjects and divided into three groups: (29) Type 2 diabetes mellitus patients and (29) diabetic patients with CAD compared with (30) healthy person. Serum relaxin-2 was determined by an enzyme immunoassay for quantitative in vitro diagnostic measurement using kit manufactured by Mybiosource (ELIZA kit), insulin by Demeditec (ELIZA kit) and Blood sugar profile including fasting blood sugar and HbA1c were done by Roche/Hitachi cobas c 311device. The mean ± SD of serum Relaxin-2 (pg/ml) of type 2 diabetic (20.65±4.14) and diabetic with CAD(17.95±5.18) patients levels showed a significant decrease (p<0.05) in comparison to that level in control group (24.28±7.31). Meanwhile Relaxin-2 level in diabetic patients with CAD demonstrate a highly significant decrease (p<0.01) in comparison to that level of control group. However, there is no significant differences (p≥0.05) between T2DM and diabetic with CAD in compare to each other. We concluded that there was a negative correlation between Relaxin-2 and FBS in diabetic patients with CAD.

Downloads

Download data is not yet available.

References

1. Ming L, Masatoshi M, Michaela E, Cleidiane GZ, Alexandra MJ and Maurice RE. Cellular localization of relaxin-like gonad-stimulating peptide expression in Asterias rubens: New insights into neurohormonal control of spawning in starfish. J Comp Neurol. 2017 May 1; 525(7): 1599–1617.

2. Linda J. Chan, K. Johan Rosengren, Sharon L. Layfield, Ross A. D. Bathgate, Frances Separovic, Chrishan S. Samuel, Mohammed A. Hossain, and John D. Wade. Identification of Key Residues Essential for the Structural Fold and Receptor Selectivity within the A-chain of Human Gene-2 (H2) Relaxin. J Biol Chem. 2012 Nov 30; 287(49): 41152–41164.

3. Samuel C S, Royce S G, Hewitson T D, Denton K M, Cooney T E and Bennett R G. Anti-fibrotic actions of Relaxin. Br J Pharmacol. 2017 May; 174(10): 962–976.

4. Joseph M Pappachan, George I Varughese, Rajagopalan Sriraman and Ganesan Arunagirinathan. Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management. World J Diabetes. 2013 Oct 15; 4(5): 177–189.

5. Hooi Hooi Ng, Chen Huei Leo, Laura J. Parry and Rebecca H. Ritchie. Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes. Front Pharmacol. 2018; 9: 501.

6. Gaetano S, Gennaro P, Celestino S, Wenjun X, Steven R, Salvatore L D’Ascia, Michele C, Nicola M, Bruno T, Theresa A. Guise, Alain L, and Andrew R. Marks. Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest. 2015 May 1; 125(5): 1968–1978.

7. Lynette P, Xiao-Jun Du, Elizabeth A. Woodcock, Helen K, Ruby C.Y. Lin, Silvana M, Robert L. Medcalf, Ziqiu M, Geoffrey A. Head, Joon Win Tan, Nelly C, Junichi S, Tetsuo S, Seigo I, Elena

V. Lukoshkova, Anthony M. Dart, Garry L. Jennings and Julie R. McMullen. Reduced Phosphoinositide 3-Kinase (p110α) Activation Increases the Susceptibility to Atrial Fibrillation. Am J Pathol. 2009 Sep; 175(3): 998–1009.

8. Enrique Caballero A. Endothelial Dysfunction in Obesity and Insulin Resistance: A Road to Diabetes and Heart Disease. Obesity Research banner, September 2012.

9. Roglic G and Unwin N. Mortality attributable to diabetes: estimates for the year 2010. Diabetes Research and Clinical Practic.2010; 87 (1): 15-19.

10. Al Hroob AM, Abukhalil MH, Hussein OE and Mahmoud AM. Pathophysiological mechanisms of diabetic cardiomyopathy and the therapeutic potential of epigallocatechin-3-gallate. Biomed Pharmacother. 2019 Jan;109:2155-2172.

11. Yuli H, Xiaoyan C, Weiyi M, Meijun Li and Yunzhao Hu. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 2016; 355.

12. David S.H. Bell. Diabetic Cardiomyopathy. Diabetes Care 2003 Oct; 26(10): 2949-2951.

13. Mukund P Srinivasan, Padmanabh K Kamath, Poornima A Manjrekar, B Unnikrishnan, Aishwarya Ullal, Mohammed Faheem Kotekar, and Chakrapani Mahabala. Correlation of Severity of Coronary Artery Disease with Insulin Resistance. N Am J Med Sci. 2013 Oct; 5 (10): 611–614.

14. Enzo B, Gianni F, Francesco C, Simonetta L, Franco M, Luciano Z, Francesca S, Maurizio P, Sandro P, Andrea R, Vittorio C, Lorenza S, Giovanni T, Riccardo B and Michele M. HOMA-Estimated Insulin Resistance Is an Independent Predictor of Cardiovascular Disease in Type 2 Diabetic Subjects. Diabetes Care 2002 Jul; 25(7): 1135-1141.

15. Masahiro Y, Takashi H, Katsuyuki M, Sayaka K, Maryam Z, Aya K, Sayuki T, Itsuko M, Akira F, Hisatomi A, Akira S, Hiroshi M, Minoru H, and Hirotsugu U. Relationship of Insulin Resistance to Prevalence and Progression of Coronary Artery Calcification Beyond Metabolic Syndrome Components. Arteriosclerosis, Thrombosis, and Vascular Biology. 2016;36:1703–1708.

16. Steven M Haffner, Heikki Miettinen and Michael P Stern. The Homeostasis Model in the San Antonio Heart Study. Diabetes Care 1997 Jul; 20(7): 1087-1092.

17. Daisuke Y, Yutaka S, Mitsuo F and Susumu S. β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians. Current Diabetes Reports June 2015, 15:36

18. Marc P and Christopher J. Nolan. Islet β -cell failure in type 2 diabetes. The American Society for Clinical Investigation, Volume 116, Issue 7 on July 3, 2006.

19. Kim DJ, Lee MS, Kim KW and Lee MK. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism. 2011; 50: 590-93.

20. Derek LR. β-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. The American Journal of Medicine, Volume 113, Issue 6, Supplement, 28 October 2002, Pages 3-11.

21. HaopengYang and XuejunLi. The role of fatty acid metabolism and lipotoxicity in pancreatic β-cell injury: Identification of potential therapeutic targets. Acta Pharmaceutica Sinica B, Volume 2, Issue 4, August 2012, Pages 396-402.

22. XiaohuiZhang, MinlingZhu, MengZhao, WenjiaChen, YuFu, YueLiu, WenxiuLiu, BoZhang, XinhuaYin and BingBai. The plasma levels of relaxin-2 and relaxin-3 in patients with diabetes. Clinical Biochemistry, Volume 46, Issues 16–17, November 2013, Pages 1713-1716.

23. Juan M. Valle Raleigh, Stefano Toldo and Anindita Das. Relaxin’ the Heart: A Novel Therapeutic Modality. Journal of cardiovascular pharmacology and therapeutics, 2015, Volume: 21 issue: 4, page(s): 353-362.

24. Kirk P. Conrad, Martyn Lewis, Elaine N. Unemori, Xinfan Huang and Carol A. Tozzi. Use of relaxin treat diseases related to vasoconstriction. United States 2004.

25. Sarwar M, Du XJ, Dschietzig TB, Summers RJ.The actions of relaxin on the human cardiovascular system. Br J Pharmacol. 2017 May;174(10):933-949.

26. Emanuela M, Silvia N, Alfredo V, Tatiana B Sacchi,Andrea N and Daniele B. Relaxin Inhibits the Activation of Human Neutrophils: Involvement of the Nitric Oxide Pathway. Endocrinology, Volume 145, Issue 3, 1 March 2004, Pages 1106–1112.

27. Sandra Feijóo-Bandín, Alana Aragón-Herrera, Diego Rodríguez-Penas, Manuel Portolés, Esther Roselló-Lletí, Miguel Rivera, José R. González-Juanatey and Francisca Lago. Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives. Front Physiol. 2017; 8: 599.

28. Gao X, Li H, Wang P, Chen H. Decreased Serum Relaxin-2 Is Correlated with Impaired Islet β-Cell Function in Patients with Unstable Angina and Abnormal Glucose Metabolism. Int Heart

J. 2018 Mar 30; 59(2):272-278.

Downloads

Published

31.10.2020

Issue

Vol. 24 No. 8 (2020): 24 (8) 2020

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

How to Cite

Huda S.Abdulghani, Sura A. Abdulsattar, & Essam N.Salman. (2020). Serum Level of Relaxin-2 Correlated to the Diabetic Patients with Coronary Artery Disease. International Journal of Psychosocial Rehabilitation, 24(8), 15313-15322. https://doi.org/10.61841/xcaacj98